Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I first-in-human, single ascending clinical study assessing OSM 0205

Next Previous
X
Search
Trial Profile

A phase I first-in-human, single ascending clinical study assessing OSM 0205

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OSM-0205 (Primary)
  • Indications Peripheral neuropathies
  • Focus Adverse reactions; First in man
  • Sponsors Osmol Therapeutics

    • Most Recent Events

    • 18 Sep 2023 According to Osmol Therapeutics media release, that the U.S. Food and Drug Administration (FDA) notified the company that the first-in-human clinical trial of OSM-0205 in healthy subjects for the prevention of CIPN may proceed.
    • 01 Aug 2023 According to Osmol Therapeutics media release, the compay has filed the Investigational New Drug application (IND) with the FDA for OSM-0205.
    • 12 Apr 2022 According to Osmol Therapeutics media release, the company expect to file IND later this year and initiate this trial in the first half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top